Following update has been provided today by Jun Takahashi (who is leading the trial)
In our clinical trial of cell transplantation for Parkinson's disease, we have completed all seven transplant operations scheduled by the end of last year. We would like to express our deep gratitude to the patients, hospital doctors, and allied health professions for their cooperation. From now on, we will enter the observation period of 2 years after surgery.
In 2020, we performed a fourth bilateral cell transplant operation. From this 4th case, dopamine neural progenitor cells manufactured by Dainippon Sumitomo Pharma Co., Ltd. are transplanted using human iPS cells established at the iPS Cell Research Institute. In addition, the cell dose has been increased from 5 million cells up to the third case to 10 million cells.
In 2021, three cases of cell transplant surgery were performed. This means that we have completed the planned cell transplantation for a total of 7 patients. At present, there are no concerns about safety, and we are carefully following up after cell transplantation.
All transplanted patients will be given an immunosuppressive drug for 1 year after transplantation, and will be followed up for 2 years to evaluate the safety and efficacy of this cell transplantation.
Autologous IP Stem Cell Update
